Conditions: Chronic Myelogenous Leukemia - Chronic Phase
Keywords: leukemia chronic myelogenous leukemia chronic phase molecular response nilotinib ENABL
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 18
Healthy volunteers: no

Brief summary:
This exploratory study will evaluate the change in molecular response in chronic myelogenous leukemia - chronic phase patients with a complete cytogenetic response and have a suboptimal molecular response to imatinib

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Nilotinib
Intervention descriptions: intervention 1: Nilotinib 300 mg is taken by mouth twice a day at 12 hour intervals. Nilotinib is to be taken with water on an empty stomach. No food two hours prior to the dose of nilotinib and for one hour following the dose.

Protocol document: